Ivonescimab halved death risk in advanced lung cancer trial
Summit's partner Akeso announced Phase III data showing ivonescimab significantly improved survival over pembrolizumab in PD-L1 positive patients, prompting the company to proceed with the ongoing global HARMONi-7 study.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day